Technophage announces FDA Fast Track Designation Granted to TP-102  for the treatment of patients with infected diabetic foot ulcers caused by Pseudomonas aeruginosa, Staphylococcus aureus and/or Acinetobacter baumannii

Technophage announces FDA Fast Track Designation Granted to TP-102  for the treatment of patients with infected diabetic foot ulcers caused by Pseudomonas aeruginosa, Staphylococcus aureus and/or Acinetobacter baumannii

Technophage announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TP-102, the company’s first bacteriophage cocktail, for the treatment of infected diabetic foot ulcers caused by three different bacteria (Pseudomonas...